Rabbit monoclonal antibody against human lysosomal associated membrane protein 3, antibody conjugate and kit and application thereof
By developing rabbit monoclonal antibodies and antibody conjugates against human lysosome-related membrane protein 3, the problem of poor antibody specificity in the prior art was solved, and high sensitivity and specific detection of CD63 protein was achieved, which is suitable for multiple The detection of species cells and pathological samples has clinical application value.
Patent Information
- Application Number
- CN202410470833.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-18
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-04-18
AI Technical Summary
The lack of excellent performance anti-human lysosomal-associated membrane protein 3 antibodies in the prior art has resulted in the lack of effective development of immunoassay technology for high sensitivity and reliability against human CD63 protein and is difficult to be used for immunologic detection.
A rabbit monoclonal antibody and antibody conjugate against human lysosomal-associated membrane protein 3, including specific light and heavy chain variable region amino acid sequences, was developed for the preparation of high specificity and high sensitivity immunity Detection kit for identification and detection of CD63 protein.
It realizes specific recognition of recombinant expression and natural CD63 protein, with 100% specificity and sensitivity, and is suitable for cell and tissue typing and tumor tissue differential diagnosis, providing high-quality immune detection guarantee.
Smart Images

Figure CN118530357B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of antibody preparation, and in particular to rabbit monoclonal antibodies against human lysosome-associated membrane protein 3, antibody conjugates and kits and applications thereof. Background Art
[0002] CD63, also known as lysosomal associated membrane protein 3 (LAMP3), consists of a short / long extracellular loop and a short N- / C-terminal cytoplasmic tail, forming a protein structure with four transmembrane protein-rich domains (TEMs) on the cell surface. CD63 is widely expressed on the surface of many cell types and is associated with various life processes such as cell activation, adhesion, mutation, and tumor invasion and metastasis. CD63 is expressed in endosomes and lysosomes. In late endosomes, CD63 is enriched on intraluminal vesicles. Through the fusion of endosomes and plasma membranes, specialized cells secrete it as exosomes. It is an important exosome-specific marker protein suitable for non-invasive detection from biological fluids. In immune responses, exosomes expressing CD63 help present antigens and activate CD4+T cells for immune regulation, which highlights the importance of CD63 in immunotherapy and its potential as a target for small molecule inhibitors. In addition, it interacts with integrins (α4β1, α3β1, α6β1, β2) and molecules such as CD81, CD82, CD9 and CD15 to control cell adhesion and migration. Other studies have shown that CD63 is expressed on activated platelets and may act as a platelet activation marker. In addition to its basic function in cell homeostasis, CD63 is expressed in a variety of tumors. CD63 tetramer protein is highly expressed in the early stages of melanoma and its expression is reduced in advanced lesions, suggesting that it may be an inhibitor of tumor progression and can be used as one of the potential targets for cancer treatment. Moreover, studies have shown that CD63 exosomes are differentially expressed in specific cancers such as ovarian cancer and lung cancer, indicating its potential use as a biomarker, opening up new avenues for early diagnosis and continuous monitoring of related diseases.
[0003] Given the multifaceted nature of the CD63 target, which is of great value in biomedical research and the clinical treatment and diagnosis of related diseases, the development of a highly specific method for detecting human lysosomal associated membrane protein 3 has broad application prospects. However, the highly sensitive and reliable immunoassay technology for human CD63 protein has not been effectively researched and developed. The main problem is the lack of high-performance anti-human lysosomal associated membrane protein 3 antibodies. Therefore, the development of human lysosomal associated membrane protein 3 monoclonal antibodies with strong specificity and good anti-interference ability has become an urgent problem to be solved. Summary of the invention
[0004] In view of the problems that the anti-human lysosomal associated membrane protein 3 antibodies in the prior art have poor specificity and are difficult to use for immunological detection, the present invention provides rabbit monoclonal antibodies and antibody conjugates against human lysosomal associated membrane protein 3, and provides the use of the rabbit monoclonal antibodies and antibody conjugates in the preparation of human lysosomal associated membrane protein 3 immunoassay kits and related kits. To achieve the aforementioned objectives, the present invention is specifically implemented through the following technical solutions:
[0005] The first aspect of the present invention provides a rabbit monoclonal antibody against human lysosomal associated membrane protein 3, comprising a light chain variable region and a heavy chain variable region, wherein the amino acid sequences of the complementary determining regions CDR1, CDR2 and CDR3 on the light chain variable region are shown as SEQ ID NO.5, SEQ ID NO.6 and SEQ ID NO.7, respectively; and the amino acid sequences of the complementary determining regions CDR1, CDR2 and CDR3 on the heavy chain variable region are shown as SEQ ID NO.8, SEQ ID NO.9 and SEQ ID NO.10, respectively.
[0006] Furthermore, the amino acid sequence of the light chain variable region is shown in SEQ ID NO.3, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.4.
[0007] Furthermore, the amino acid sequence of the light chain of the rabbit monoclonal antibody is shown in SEQ ID NO.1, and the amino acid sequence of the heavy chain is shown in SEQ ID NO.2.
[0008] Furthermore, the rabbit monoclonal antibody is a full-length antibody or an antibody fragment with immunological activity; the antibody fragment is selected from at least one of a Fab fragment, a F(ab)2 fragment, a Fv fragment, a (Fv)2 fragment, a scFv fragment and a sc(Fv)2 fragment.
[0009] The second aspect of the present invention provides an antibody conjugate, comprising the rabbit monoclonal antibody against human lysosomal associated membrane protein 3 as described above, and a detection label connected to the rabbit monoclonal antibody.
[0010] Furthermore, the detection label is selected from one or more of biotin, fluorescein, chemiluminescent group, chemical fluorescent group, fluorescent protein, horseradish peroxidase, acid phosphatase, colloidal gold, colored magnetic beads, magnetic microspheres, latex particles, radioactive nuclides and detection antibodies.
[0011] The third aspect of the present invention provides a nucleic acid molecule, a recombinant vector or a host cell comprising the nucleic acid molecule, wherein the nucleic acid molecule is used to encode the rabbit monoclonal antibody against human lysosomal associated membrane protein 3 as described above.
[0012] The fourth aspect of the present invention provides the use of the above-mentioned rabbit monoclonal antibody or antibody conjugate against human lysosomal associated membrane protein 3 in the preparation of a human lysosomal associated membrane protein 3 immunoassay kit.
[0013] A fifth aspect of the present invention provides a human lysosome-associated membrane protein 3 immunoassay kit, which comprises the rabbit monoclonal antibody or antibody conjugate against human lysosome-associated membrane protein 3 as described above.
[0014] Furthermore, the kit is an immunoblotting kit or an immunohistochemistry kit.
[0015] The advantages and positive effects of the present invention are:
[0016] The anti-human lysosomal associated membrane protein 3 rabbit monoclonal antibody of the present invention can specifically recognize recombinantly expressed and natural CD63 proteins on the surface of cells / tissues, has good specificity and high sensitivity, can effectively achieve the purpose of tissue and cell typing and tumor tissue differential diagnosis, has a specificity and sensitivity of up to 100%, provides a solid guarantee for high-quality immunodetection of CD63 protein, is suitable for the detection of various cells / tissues and pathological samples, and is particularly suitable for large-scale, large-sample, and multi-group immunohistochemical staining in cell smear research, and has great clinical application value. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the following briefly introduces the drawings required for use in the description of the embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.
[0018] Figure 1 This is the SDS-PAGE gel electrophoresis diagram of CD63 in Example 1 of the present invention;
[0019] Figure 2 The expression map of the mammalian pRB322 vector used for constructing the anti-human CD63 rabbit monoclonal antibody expression vector in Example 2 of the present invention, from left to right, respectively, the vectors carrying the antibody light chain constant region and heavy chain constant region in advance;
[0020] Figure 3 This is a WB result diagram of the anti-human CD63 rabbit monoclonal antibody of Example 3 of the present invention detecting human CD63 in a human malignant melanoma cell sample;
[0021] Figure 4 This is an IHC result diagram of the anti-human CD63 rabbit monoclonal antibody of Example 4 of the present invention detecting CD63 in a human malignant melanoma tissue sample;
[0022] Figure 5 This is a diagram showing the IHC results of the anti-human CD63 rabbit monoclonal antibody of Example 4 of the present invention detecting CD63 in a human colon tissue sample;
[0023] Figure 6 This is a diagram showing the IHC results of detecting CD63 in human breast cancer tissue samples using the anti-human CD63 rabbit monoclonal antibody of Example 4 of the present invention. DETAILED DESCRIPTION
[0024] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with embodiments. The embodiments described herein are only used to explain the present invention and are not used to limit the present invention.
[0025] Based on the information contained in the present invention, it is easy for those skilled in the art to make various changes to the precise description of the present invention without departing from the spirit and scope of the appended claims. It should be understood that the scope of the present invention is not limited to the defined processes, properties or components, because these embodiments and other descriptions are only for the purpose of illustrating specific aspects of the present invention. In fact, various changes that a person skilled in the art or related fields can obviously make to the embodiments of the present invention are covered within the scope of the appended claims.
[0026] In order to better understand the present invention but not to limit the scope of the present invention, all the numbers and other numerical values used in the present invention to express the amount, percentage, etc. should be understood as modified by the word "about" in all cases. Therefore, unless otherwise specified, the numerical parameters listed in the specification and the appended claims are approximate values, which may be changed according to the different ideal properties to be obtained. Each numerical parameter should at least be regarded as obtained according to the reported significant figures and by conventional rounding methods.
[0027] In addition, it should be noted that, unless otherwise defined, in the context of the present invention, the scientific and technical terms used should have the meanings commonly understood by those of ordinary skill in the art.
[0028] The meaning of the terms "include", "comprising", "containing", "having" and the like is non-restrictive, i.e., other steps and other ingredients that do not affect the result may be added. The term "and / or" is regarded as a specific disclosure of each of the two specified features or components with or without the other. For example, "A and / or B" is regarded as including the following situations: (i) A, (ii) B, and (iii) A and B.
[0029] The terms "monoclonal antibody", "monoclonal antibody", "antibody" and other similar terms have the same meaning and are used interchangeably to refer to a rabbit monoclonal antibody that specifically binds to human lysosomal associated membrane protein 3 (LAMP3, also known as CD63). The modifier "rabbit" indicates that the complementarity determining region (CDR) of the antibody is derived from a rabbit immunoglobulin sequence.
[0030] An antibody is an immunoglobulin molecule that can specifically bind to a target antigen or epitope through at least one antigen recognition site located in the variable region of the immunoglobulin molecule. In the present invention, the term "antibody" should be interpreted in the broadest sense and includes different antibody structures, including but not limited to so-called full-length antibodies, antibody fragments, and their genetic or chemical modifications, as long as they exhibit the desired antigen binding activity. Among them, "antibody fragment" refers to one or more parts or fragments of a full-length antibody. In typical examples, antibody fragments include: Fab, Fab', F(ab)2, F(ab')2, Fv, (Fv)2, scFv, sc(Fv)2.
[0031] A typical antibody molecule (full-length antibody) consists of two identical light chains (L) and two identical heavy chains (H). Light chains can be divided into two types, namely κ chain and λ chain; heavy chains can be classified into five types, namely μ, δ, γ, α and ε chains, and antibodies are defined as IgM, IgD, IgG, IgA and IgE, respectively. The amino acid sequences near the N-terminus of the heavy and light chains vary greatly, while the amino acid sequences of other parts are relatively constant. The regions near the N-terminus of the light and heavy chains where the amino acid sequences vary greatly are called variable regions (V), and the regions near the C-terminus where the amino acid sequences are relatively stable are called constant regions (C). The heavy chain variable region (VH) and the light chain variable region (VL) are usually the most variable parts of the antibody and contain antigen recognition sites. The VH and VL regions can be further subdivided into hypervariable regions (HVR) and framework regions (FR). The hypervariable regions are also called complementarity determining regions (CDRs), which are ring-shaped structures. The heavy chain CDR and the light chain CDR are closely together and cooperate with each other through the FR region, forming a surface that can complement the three-dimensional structure of the target antigen or epitope, which determines the specificity of the antibody and is the site where the antibody recognizes and binds to the antigen. The FR region is the more conservative part of VH and VL. They are generally in a β-folded configuration and are connected by three CDRs that form a connecting loop. Each VH and VL is usually composed of three CDRs and four FRs, arranged from the amino terminus to the carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
[0032] CDRs can be identified according to the Kabat definition, the Chothia definition, the accumulation of both the Kabat definition and the Chothia definition, the AbM definition, the contact definition, the IMGT unique numbering definition and / or the conformational definition, or any CDR determination method known in the art. As used herein, CDRs are defined by the Kabat numbering system.
[0033] The light chain constant region (CL) and the heavy chain constant region (CH) are not directly involved in the binding of antibodies to antigens, but they exhibit different effector functions, such as participating in antibody-dependent cytotoxicity of antibodies. The length of CL of different types of Ig (κ or λ) is basically the same, but the length of CH of different classes of Ig is different, such as IgG, IgA and IgD include CH1, CH2 and CH3, while IgM and IgE include CH1, CH2, CH3 and CH4. The amino acid sequences of the heavy chain and light chain constant regions of antibodies are well known in the art.
[0034] A full-length antibody is the most complete antibody molecular structure and has a typical Y-shaped molecular structure. Therefore, in the context of the present invention, "full-length antibody", "complete antibody" and "Y-shaped antibody" have the same meaning and can be used interchangeably.
[0035] The term "antigen-binding fragment (Fab)" refers to the region of an antibody molecule that can bind to an antigen. It consists of a complete light chain (variable region and constant region) and a partial heavy chain (variable region and a constant region fragment). By proteolytic cleavage of the full-length antibody, fragments such as Fab, F(ab')2, and Fab' can be obtained. For example, under the action of papain, IgG can be degraded into two Fab fragments and an Fc fragment; under the action of pepsin, IgG can be degraded into a F(ab')2 fragment and a pFc' fragment. The F(ab')2 fragment is further reduced to form two Fab' fragments. Because Fab has an antigen-binding region and a partial constant region, it not only has the same antibody-antigen affinity and excellent tissue penetration as a single-chain antibody (scFv), but also has a more stable structure, and is widely used in clinical diagnosis and treatment.
[0036] The term "variable fragment (Fv)" is located at the N-terminus of the antibody Fab fragment, contains only the variable region, and is composed of the variable regions of a light chain and a heavy chain. It is a dimer of VH and VL non-covalently bound (VH-VL dimer). The three CDRs of each variable region interact with each other to form an antigen binding site on the surface of the VH-VL dimer, which has the ability to recognize and bind to antigens, although the affinity is lower than that of a complete antibody.
[0037] The term "single-chain variable fragment (scFv)" refers to the smallest antibody fragment formed by connecting the heavy chain variable region (VH) and the light chain variable region (VL) through a flexible linker (generally composed of 10-25 amino acids), which retains the binding specificity of the original antibody to the antigen. The linker in the present invention is not particularly limited as long as it does not hinder the expression of the antibody variable regions connected to its two ends. Compared with full-length antibodies, scFv has the characteristics of small molecular weight, so it has higher penetration and lower immune side effects.
[0038] The full-length sequence of the antibody or antibody fragment of the present invention can be from a single species, such as a rabbit, or can be a chimeric or humanized antibody to reduce the body's rejection reaction while maintaining the required specificity and affinity. The term "chimeric antibody" refers to a portion of an antibody derived from a specific source or species, while the rest is derived from a different source or species. The term "humanized antibody" is a chimeric antibody of a non-human antibody such as a rabbit antibody CDR region and a human FR region. In some cases, the variable region of a non-human antibody is combined with a constant region of a human antibody, such as a human-rabbit chimeric antibody; in other cases, the CDR region of a non-human antibody is combined with a FR region and a constant region derived from a human antibody sequence, that is, the CDR region of a non-human antibody is grafted onto a human antibody framework (FR) sequence, and this framework sequence is derived from a single or multiple other human antibody variable region framework sequences. In the present invention, the CDR region in a chimeric antibody or humanized antibody is derived from a rabbit CDR region.
[0039] The term "monoclonal antibody" refers to a homogeneous antibody population, i.e., the individual antibodies constituting the population are identical except for possible naturally occurring mutations and / or post-translational modifications (e.g., isomerization, amidation) that may be present in small amounts. Monoclonal antibodies are highly specific, directed against a single antigen or epitope. "Monoclonal" indicates that the antibody is characterized by being obtained from a substantially homogeneous antibody population and should not be construed as limiting the structure, source, or preparation of the antibody. In certain embodiments, monoclonal antibodies are prepared by hybridoma methods, phage display methods, yeast display methods, recombinant DNA methods, single cell screening, or single cell sequencing methods.
[0040] The term "specific binding" is a well-known term in the art, and a molecule exhibits "specific binding" if it reacts with a specific target antigen or epitope more frequently, more rapidly, longer lastingly, and / or with greater affinity than with other target antigens or epitopes. "Specific binding" or "preferential binding" does not necessarily require (although it can include) exclusive binding.
[0041] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, specific embodiments of the present invention are described in detail below with reference to the accompanying drawings.
[0042] An embodiment of the present invention provides a rabbit monoclonal antibody against human lysosomal associated membrane protein 3, comprising a light chain variable region and a heavy chain variable region, wherein the light chain variable region and the heavy chain variable region both include three complementary determining regions (CDRs), which are named CDR1, CDR2 and CDR3, respectively, wherein the amino acid sequences of CDR1, CDR2 and CDR3 on the light chain variable region are shown in SEQ ID NO.5, SEQ ID NO.6, and SEQ ID NO.7, respectively; the amino acid sequences of CDR1, CDR2 and CDR3 on the heavy chain variable region are shown in SEQ ID NO.8, SEQ ID NO.9 and SEQ ID NO.10, respectively.
[0043] The present invention uses the complete extracellular domain of human lysosomal associated membrane protein 3 (CD63) protein as an antigen to immunize rabbits, thereby preparing rabbit monoclonal antibodies against human lysosomal associated membrane protein 3. The obtained antibodies can specifically recognize recombinantly expressed and natural CD63 proteins on the surface of cells / tissues, and have good specificity and high sensitivity. The human malignant melanoma cell A-375 sample expressing CD63 protein is detected by Western blotting, and the antibodies can accurately detect the target band. The antibodies can accurately distinguish 7 positive samples from 6 negative samples by immunohistochemistry to detect multiple tissues expressing CD63 protein. The positive samples are obviously stained, the background is clean, and there is no non-specific staining. The purposes of tissue and cell typing and tumor tissue differential diagnosis can be effectively achieved, and the specificity and sensitivity are as high as 100%. It is confirmed that the antibodies of the present invention have high accuracy, good reliability and excellent anti-interference ability in immunodetection of CD63 protein, provide a solid guarantee for high-quality immunodetection of CD63 protein, are suitable for the detection of various cells / tissues and pathological samples, and are particularly suitable for large-scale, large-sample and multi-group immunohistochemical staining in cell smear research, and have great clinical application value.
[0044] Optionally, the light chain variable region and the heavy chain variable region each include four framework regions (FRs), and the four FRs and three CDRs are arranged alternately in sequence to form a variable region. The amino acid sequence of VL of the rabbit monoclonal antibody of the present invention is shown in SEQ ID NO.3, and the amino acid sequence of VH is shown in SEQ ID NO.4.
[0045] Optionally, the rabbit monoclonal antibody of the present invention further comprises a light chain constant region and a heavy chain constant region, CL and VL constitute a complete light chain, and CH and VH constitute a complete heavy chain. The constant region of an antibody can usually be obtained by public query, such as: searching for rabbit IgG gamma C reign to obtain CH through the IMGT online database (www.imgt.org), and searching for rabbit IgG Kappa Creign to obtain CL. Specifically, the amino acid sequence of the light chain comprising the light chain constant region is shown in SEQ ID NO.1, and the amino acid sequence of the heavy chain comprising the heavy chain constant region is shown in SEQ ID NO.2.
[0046] It should be noted that the rabbit monoclonal antibody of the present invention can be a full-length antibody (having a typical Y-shaped molecular structure) or an antibody fragment. The antibody fragment refers to a polypeptide that substantially retains the same biological function or activity as the full-length form of the rabbit monoclonal antibody. Specifically, the antibody fragment includes the CDR region as described above, and more preferably has the variable region as described above, thereby retaining a complete antigen recognition and binding site, and can bind to the same antigen as the full-length antibody, especially to the same epitope. The antibody fragments include, but are not limited to: (i) Fab fragments, which are monovalent fragments consisting of the variable region and the first constant region of each heavy chain and light chain; (ii) F(ab)2 fragments, which are bivalent fragments comprising two Fab fragments connected by a disulfide bridge in the hinge region; (iii) Fv fragments, which are composed of one heavy chain variable region and one light chain variable region of an antibody; (iv) (Fv)2 fragments, which are composed of two covalently linked Fv fragments; (v) scFv fragments, which are Fv fragments consisting of a single polypeptide chain, in which one heavy chain variable region and one light chain variable region are connected by a linker; (vi) sc(Fv)2 fragments, which are formed by connecting two heavy chain variable regions and two light chain variable regions by a linker, etc. These antibody fragments can be obtained by conventional techniques in the art.
[0047] Another embodiment of the present invention provides an antibody conjugate, comprising the rabbit monoclonal antibody against human lysosomal associated membrane protein 3 as described above, and a detection label connected to the rabbit monoclonal antibody.
[0048] The detection label is used to generate a recognizable signal change to identify the sample to be tested according to the signal change. The detection label includes, but is not limited to: biotin, fluorescein, chemiluminescent group, chemical fluorescent group, fluorescent protein, enzyme (such as horseradish peroxidase, acid phosphatase), colloidal gold, colored magnetic beads, magnetic microspheres, latex particles, radionuclides, detection antibodies or combinations thereof.
[0049] Another embodiment of the present invention provides a nucleic acid molecule, a recombinant vector or a host cell comprising the nucleic acid molecule, wherein the nucleic acid molecule is used to encode the rabbit monoclonal antibody against human lysosomal associated membrane protein 3 as described above.
[0050] Nucleic acid molecules can be in the form of DNA (e.g., cDNA, genomic DNA, or synthetic DNA) or RNA (e.g., mRNA or synthetic RNA). DNA can be single-stranded or double-stranded, and can be a coding strand or a non-coding strand. The sequence of the nucleic acid molecule can be derived from the amino acid sequence of the antibody by conventional means such as codon coding rules. The full-length sequence of the nucleic acid molecule or its fragments can usually be obtained by PCR amplification, recombination, or artificial synthesis.
[0051] The starting vector for constructing the recombinant vector can be any conventional vector in the art as long as it can hold the nucleic acid molecule, and typical vectors include plasmids, viral vectors, bacteriophages, cosmids, and minichromosomes. The vector can be a cloning vector (i.e., used to transfer the nucleic acid molecule to a host and multiply it in a host cell) or an expression vector (i.e., containing necessary genetic elements to allow the nucleic acid molecule inserted into the vector to be expressed in the host cell). Therefore, the cloning vector can include a selection marker, and a replication origin that matches the cell type specified by the cloning vector, while the expression vector includes regulatory elements (such as promoters, enhancers) expressed in the specified host cell. The nucleic acid molecule of the present invention can be inserted into a suitable vector to form a cloning vector or an expression vector. This is a known technology in the art and will not be described in detail here.
[0052] The nucleic acid molecules encoding the heavy and light chains of the antibodies of the present invention can be constructed into two vectors, respectively, which can be introduced into the same or different host cells. When the heavy and light chains are expressed in different host cells, each chain can be separated from the host cells expressing them, and the separated heavy and light chains are mixed and incubated under suitable conditions to form antibodies. In other embodiments, the nucleic acid molecules encoding the heavy and light chains of the rabbit monoclonal antibodies of the present invention can also be cloned into a vector, and each nucleic acid sequence is connected to a suitable promoter downstream; for example, each nucleic acid sequence encoding the heavy and light chains can be operably connected to different promoters, or the nucleic acid sequences encoding the heavy and light chains can be operably connected to a single promoter, so that both the heavy and light chains can be expressed by the same promoter. The choice of expression vector / promoter depends on the type of host cell used to produce the antibody.
[0053] In the present invention, the recombinant vector is transfected or transformed into the host cell using conventional techniques. When the host is a prokaryotic organism such as Escherichia coli, competent cells that can absorb DNA can be harvested after the exponential growth phase and treated with CaCl2 or MgCl2. If necessary, microinjection, electroporation or liposome packaging can also be used. When the host is a eukaryotic organism, the following DNA transfection methods can be selected: calcium phosphate coprecipitation, microinjection, electroporation, liposome packaging, etc.
[0054] The host cell can be a prokaryotic cell, such as a bacterial cell; or a lower eukaryotic cell, such as a yeast cell; or a higher eukaryotic cell, such as a mammalian cell. Representative examples include: Escherichia coli, Streptomyces, Salmonella typhimurium, yeast, Drosophila S2 or Sf9 cells, CHO, COS7, 293 series cells, etc. After obtaining the host cell transfected or transformed with the vector described above, it can be cultured under suitable conditions to express the monoclonal antibody, and then separated to obtain the purified antibody.
[0055] In a preferred embodiment, the starting vector of the above-mentioned recombinant vector is the mammalian expression vector pBR322, and the host cell is a human kidney epithelial cell (293F cell).
[0056] Still another embodiment of the present invention provides the use of the above-mentioned anti-human lysosomal associated membrane protein 3 rabbit monoclonal antibody or antibody conjugate in the preparation of a human lysosomal associated membrane protein 3 immunoassay kit.
[0057] The advantages of using the rabbit monoclonal antibody or antibody conjugate against human lysosomal associated membrane protein 3 in preparing a human lysosomal associated membrane protein 3 immunoassay kit are the same as the advantages of the rabbit monoclonal antibody against human lysosomal associated membrane protein 3 over the prior art as described above, and will not be repeated here.
[0058] Based on the same inventive concept, an embodiment of the present invention further provides a human lysosome-associated membrane protein 3 immunoassay kit, which comprises the rabbit monoclonal antibody or antibody conjugate against human lysosome-associated membrane protein 3 as described above.
[0059] It should be noted that the antibody of the present invention can be used alone or combined or coupled with a detection marker to form an antibody conjugate. In some embodiments, the antibody of the present invention is used as an antigen-binding antibody, which specifically recognizes and binds to the CD63 protein in the sample to be tested, and then produces a recognizable signal change through the detection marker connected thereto to achieve qualitative or quantitative detection of the CD63 protein. In other embodiments, the anti-human CD63 protein antibody (as a primary antibody or capture antibody) is not labeled, and the detection marker is coupled to a secondary antibody (as a detection antibody) or other molecules that can bind to the primary antibody. For example, if the anti-human CD63 protein antibody is a rabbit IgG antibody, then the secondary antibody can be an anti-rabbit IgG antibody, thereby generating a recognizable signal change after the secondary antibody coupled to the detection marker specifically binds to the antibody of the present invention, thereby achieving qualitative or quantitative detection.
[0060] The above-mentioned immunoassay methods include but are not limited to: enzyme immunoassay (EIA), enzyme linked immunosorbent assay (ELISA), enzyme-linked immunospot (ELISPOT), immunohistochemistry (IHC), immunofluorescence (IF), Western blot (WB), immunoprecipitation (IP) and flow cytometry (FC).
[0061] In a preferred embodiment, the immunodetection method is immunoblotting or immunohistochemistry, and the kit is an immunoblotting kit or an immunohistochemistry kit.
[0062] The present invention is further described below in conjunction with specific examples. The experimental methods in the following examples where specific conditions are not specified are usually performed under conventional conditions, such as the conditions described in the Molecular Cloning Laboratory Guide (Fourth Edition) published by Cold Spring Harbor Laboratory, or usually under the conditions recommended by the manufacturer.
[0063] Example 1 Preparation of human CD63 protein antigen
[0064] The present invention selects the complete extracellular domain of human lysosomal associated membrane protein 3 (LAMP3, also known as CD63) as an antigen. The NCBI number of CD63 is NP_001771.1, and the Uniprot ID is P08962. The complete extracellular domain is a fragment of amino acids from positions 103 to 203. The gene sequence corresponding to 103-203AA of human CD63 protein (NCBI number is NM_001780.6) is constructed into a pGEX-4T-AB1 vector, and the protein is transfected into Escherichia coli Rosetta for expression to obtain a human CD63 recombinant protein with high purity, which is used as an antigen to immunize animals.
[0065] 1. Construction of protein expression plasmid
[0066] A plasmid containing the human CD63 CDS sequence (from Wuhan Abotek Biotechnology Co., Ltd.) was used as a template to amplify the 103-203AA fragment of the human CD63 protein with a pair of specific primers; the PCR reaction system was as follows: 1 μL template, 1 μL forward primer (10 mM), 1 μL reverse primer (10 mM), 25 μL 2×Gloria Hi-Fi PCR Master Mix with GCBuffer (from Wuhan Abotek Biotechnology Co., Ltd., catalog number RK20717) and 22 μL NF H2O; PCR amplification program: pre-denaturation at 98°C for 30 s, followed by 30 cycles of 98°C for 10 s, 64°C for 30 s, and 72°C for 30 s, and finally kept at 72°C for 5 min, and the resulting reaction solution was stored at 4°C.
[0067] The sequence of the amino acid fragment from position 103 to position 203 of the human CD63 protein (see SEQ ID NO.11) is as follows:
[0068] AGYVFRDKVMSEFNNNFRQQMENYPKNNHTASILDRMQADFKCCGAANYTDWEKIP SMSKNRVPDSCCINVTVGCGINFNEKAIHKEGCVEKIGGWLRKNV.
[0069] The nucleotide sequences of the forward primer and the reverse primer (see SEQ ID NO.12-13) are:
[0070] CD63-F: GGTTCCGCGTGGATCCCCGGAAGCTGGCTATGTGTTTAGAGATAAGG;
[0071] CD63-R: TGGTGATGATGATGCGGCCGCTCCACATTTTTCCTCAGCCAGCC.
[0072] After the amplified PCR product was purified, it was loaded onto the expression vector by homologous recombination. The prokaryotic expression vector used was pGEX-4T-1 (commercial vector). The plasmid was preserved after sequencing verification. The sequencing work was completed by Jin Kairui Biotechnology Co., Ltd.
[0073] 2. CD63 protein expression
[0074] The pGEX-4T-AB1 plasmid containing the 103-203AA fragment of the human CD63 protein was transformed into the E. coli Rosetta strain and incubated overnight at 37°C on an LB plate containing 100 μg / mL ampicillin to obtain several single colony transformants. The single colony transformants were inoculated into 2 mL LB culture medium (containing 100 μg / mL ampicillin) and cultured at 37°C and 220 rpm for 3-4 h until the OD 600nm Next, 2 mL of culture of each strain was transferred to 400 mL of LB expression medium and cultured at 37°C and 220 rpm for another 3-4 h. 600nm When it reaches about 0.45-0.55, add 0.8mM IPTG and induce at 37℃ for 3-4h. Centrifuge the induced bacterial solution at 4000rpm for 10min, discard the supernatant, and store the bacteria in a -20℃ freezer.
[0075] Take 30mL of lysis solution (50mM Tris-300mM NaCl) to suspend the bacteria in a centrifuge bottle. Transfer the suspended bacterial solution to a 50mL round-bottom centrifuge tube, put it in an ice box, and fix it with ice. Select the amplitude changer, put it in the lysis chamber, power 350W, lysis time 3s, interval time 3s, countdown 5min, then place it in an ice-water mixture to cool for 5min, and repeat the above steps to lysis for 5min. After lysis, centrifuge at 9000rpm for 10min to obtain the supernatant and precipitate.
[0076] Second disruption: Measure 30 mL of lysis solution (2 M urea-PBS buffer) and pour it into the precipitate. Blow the precipitate evenly and transfer it to a 50 mL round-bottom centrifuge tube. Use a power of 350 W, a lysis time of 3 s, an interval of 3 s, and disruption for 0 to 5 min (the disruption time is determined by the amount and texture of the precipitate. The bacterial solution is placed in ice). Centrifuge at 9000 rpm for 10 min to obtain the supernatant and inclusion bodies. The inclusion bodies are diluted 5 times (abbreviated as "*5"). Figure 1 The SDS-PAGE electrophoresis diagram of the inclusion bodies is shown on the left side of the marker (MK), from which it can be seen that the CD63 (103-203AA)-GST protein is expressed in the inclusion bodies.
[0077] 3. CD63 protein purification
[0078] The CD63 protein was extracted and purified from inclusion bodies by affinity chromatography using GST affinity chromatography resin (purchased from Huiyan, product number HQ030307001L). The SDS-PAGE electrophoresis pattern of the purified protein is as shown Figure 1 to the right of the marker (MK) in Figure 1 . In Figure 1 , the lane "Inclusion" represents inclusion bodies, the lanes "0.4" and "0.2" represent BSA at 0.4 mg / mL and 0.2 mg / mL, the lane "MK" represents the marker, the lane "FT" represents the flow-through during the purification process, the lane "*5" represents the purified product of inclusion bodies, 300-1 represents a protein concentration of 0.8 mg / mL, 300-2 represents a protein concentration of 0.1 mg / mL, and 500 represents a protein concentration of 0.5 mg / mL. From
[0079] Example 2 Preparation of Rabbit Monoclonal Antibody Against Human Lysosome-Associated Membrane Protein 3
[0080] 1. Animal Immunization
[0081] Using the recombinant human CD63 protein (prepared and purified in Example 1) as the immunogen, 2 New Zealand white rabbits were immunized; each rabbit was immunized with 300 μg of the immunogen. Before the first immunization, the immunogen was mixed with an equal amount of complete Freund's adjuvant (purchased from Sigma) to make an emulsifier, and injected subcutaneously at multiple points on the abdomen and back of the rabbit; every 3 weeks after the first immunization, 150 μg of the immunogen was mixed with an equal amount of incomplete Freund's adjuvant (purchased from Sigma) to make an emulsifier, and injected subcutaneously at multiple points on the abdomen and back of the rabbit for two booster immunizations. After three immunizations, rabbit serum samples were collected. The serum was diluted 1:243000 and its titer against human CD63 protein was measured by ELISA. For rabbits with an OD 450nm exceeding 0.2, they were boosted by subcutaneous multi-point injection with 200 μg of the immunogen. Three days later, the animals were sacrificed and the spleens were taken.
[0082] 2. Isolation of B lymphocytes in the spleen and sorting of B lymphocytes
[0083] B lymphocytes in the spleen were isolated by conventional methods, and then antigen-specific B lymphocytes were sorted. For related methods, refer to the patents "Method for Efficiently Isolating Single Antigen-Specific B Lymphocytes from Spleen Cells (Publication No.: CN110016462A, Publication Date: July 16, 2019)" and "An In Vitro Culture System for B Lymphocytes and Its Application (Publication No.: CN111518765A, Publication Date: August 11, 2020)".
[0084] 3. Cloning of the gene encoding rabbit monoclonal antibody
[0085] After culture, the supernatant of B cells was used to identify positive clones by antigen-coated ELISA. The cells of positive clones were collected and lysed and then analyzed by Quick-RNA TM RNA was extracted using MicroPrep kit (purchased from ZYMO, catalog number R1100-250) and reverse transcribed into cDNA. Using cDNA as a template, the naturally paired rabbit monoclonal antibody light chain variable region (VL) and heavy chain variable region (VH) genes were amplified from the cDNA of the corresponding positive clones by PCR. The PCR reaction system included: 4 μL cDNA, 1 μL forward primer (10 mM), 1 μL reverse primer (10 mM), 12.5 μL 2×GloriaHiFi (purchased from Wuhan Abotek Biotechnology Co., Ltd., catalog number RK20717) and 6.5 μL H2O. The PCR amplification program included: 98°C pre-denaturation for 30 s, followed by 40 cycles of 98°C for 10 s, 64°C for 30 s, and 72°C for 30 s, and finally kept at 72°C for 5 min. The resulting reaction solution was stored at 4°C. The primer pair sequences (5'-3') for amplifying VL and VH genes are as follows (see SEQ ID NO.14-17), where F and R represent forward and reverse primers, respectively:
[0086] VL-Primer-F: tgaattcgagctcggtacccATGGACACGAGGGCCCCCAC;
[0087] VL-Primer-R: cacacacacgatggtgactgTTCCAGTTGCCACCTGATCAG;
[0088] VH-Primer-F: tgaattcgagctcggtacccATGGAGACTGGGCTGCGCTG;
[0089] VH-Primer-R: gtagcctttgaccaggcagcCCAGGGTCACCGTGAGCTG.
[0090] The amplified cDNA was sequenced by Jinkairui Biotechnology Co., Ltd. to obtain the variable region (VL and VH) amino acid sequence; then the constant region amino acid sequence was obtained by querying the IMGT online database (www.imgt.org). The antibody sequence is shown in Table 1.
[0091] Table 1 Sequence information of rabbit monoclonal antibodies in this example
[0092]
[0093] 4. Production and purification of rabbit monoclonal antibodies
[0094] The heavy chain genes and light chain genes of several selected rabbit monoclonal antibodies were loaded on expression vectors respectively. The mammalian expression vector pBR322 used carried the rabbit monoclonal antibody light chain constant region (CL) and heavy chain constant region (CH) genes. The expression profile is shown in Figure 2 In the figure, pRB322 origin and f1 origin are replication promoters in E. coli, Ampcillin is a plasmid resistance gene, CMV immearly promoter is a promoter in eukaryotes, SV40PA terminator is a tailing signal, Light chain constant is the nucleic acid sequence of the light chain constant region (left figure), and Heavy chain constant is the nucleic acid sequence of the heavy chain constant region (right figure). The variable region genes containing signal peptides amplified in the above steps were constructed into the upstream of the CL and CH genes of the corresponding expression vector pBR322 to obtain light chain gene and heavy chain gene expression vectors, and the expression vectors were successfully constructed by sequencing.
[0095] The signal peptide of this embodiment adopts the antibody expression signal peptide sequence commonly used in the art, such as the light chain variable region upstream signal peptide "MDTRAPTQLLGLLLLWLPGARC" of the patent "Anti-human interferon α2 rabbit monoclonal antibody and its application (publication number: CN116063487A, publication date: 2023-05-05)" and the patent "High-affinity Human IL-5 rabbit monoclonal antibody and its application (publication number: CN115819578A, publication date: 2023-03-21)", and the heavy chain variable region upstream has a signal peptide "METGLRWLLLVAVLKGVQC".
[0096] The expression vectors containing the light chain gene and the heavy chain gene were transfected into 293F cells together, and cultured for 72-96 hours after transfection to obtain the recombinant antibody that recognizes human CD63 in the culture supernatant. The recombinant rabbit monoclonal antibody that recognizes human CD63 protein was purified from the culture supernatant after transfection using proteinA affinity gel resin (purchased from Tiandi Renhe, catalog number SA023100). The antibody purity was verified to be ≥95% using 12% SDS-PAGE gel electrophoresis, and the concentration was 0.4 mg / mL. The purified antibody was aliquoted and stored at -20°C for later use.
[0097] Example 3 Immunoblotting analysis (WB) of CD63 rabbit monoclonal antibody
[0098] Human malignant melanoma cells A-375 with high expression of CD63 were taken and subcultured in a 48-well cell culture plate. When the confluence was 70-80%, the culture supernatant was aspirated, the cells were carefully washed twice with PBS solution, the cells were lysed and subjected to 7% polyacrylamide gel electrophoresis, and then the protein bands on the gel were transferred to the PVDF membrane in the electrotransfer system according to the routine operation, the membrane was placed in TBST blocking solution containing 3% skim milk powder and incubated at room temperature for 1 hour, purified CD63 rabbit monoclonal antibody (1:1000 dilution) was added, and incubated at 4°C overnight; after washing the membrane with TBST, a 1:100000 dilution of goat anti-rabbit secondary antibody (from Wuhan Abotek Biotechnology Co., Ltd., product number AS014) was added and incubated at room temperature for 1 hour; the membrane was washed with TBST again, ECL ultrasensitive colorimetric solution was added, and the results are shown in FIG. Figure 3 .
[0099] CD63 protein is a four-transmembrane protein with a total length of 238AA and three glycosylation sites on the surface. Glycosylation will affect the size of the protein, so the theoretical molecular weight of CD63 is between 30-60KD. Figure 3 It can be seen that the screened CD63 rabbit monoclonal antibody has good specificity and can detect a thick target band that is consistent with the size of the target protein.
[0100] Example 4 Immunohistochemical analysis (IHC) of CD63 rabbit monoclonal antibody
[0101] Human CD63 protein is highly expressed in the cytoplasm and cell membrane of monocytes, and the cytoplasm and cell membrane of macrophages, and is also used for auxiliary diagnosis of malignant melanoma. The positive samples selected include 1 human lung, 1 human lung cancer, 1 human colon, 2 human colon cancers, 1 human tonsil, and 1 human malignant melanoma. The negative samples selected include 1 human esophagus, 1 human esophageal cancer, 1 human placenta, 1 human liver, 1 human liver cancer, and 1 human breast cancer. Among them, only macrophages and monoclonal antibody cells in human breast cancer are positive, and the rest of the cells are negative, so it is judged to be negative.
[0102] Immunohistochemistry (IHC) staining was performed according to the instructions for pathology chip-09-03 customized by Wuhan Saiweier Biotechnology Co., Ltd., which specifically includes the following steps: 1) Sample preparation and baking: Place the paraffin sections on the slice rack in the same direction and bake them in a 56°C constant temperature box for 30 minutes; at the same time, put a cylinder of dewaxing solution (purchased from Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd.) into a 56°C constant temperature box; 2) Dewaxing to water: Place the paraffin sections together with the slice rack into a cylinder of dewaxing solution 1, then take them out of the constant temperature box and place them at room temperature. After 5 minutes, take out the sections and immerse them in a cylinder of room temperature dewaxing solution 2, and place the paraffin sections into the cylinders in the order of dewaxing solution 2, dewaxing solution 3, anhydrous ethanol 1, anhydrous ethanol 2, and anhydrous ethanol 3. When placed in the dewaxing solution reagent cylinder, each cylinder is placed for 5 minutes, and when placed in the anhydrous ethanol reagent cylinder, each cylinder is placed for 3 minutes; wash the sections with running water for 3 minutes; 3) Antigen repair: 0.01M sodium citrate repair solution (pH 6.0) Perform high-pressure heat repair (high-pressure heat repair is to heat the repair solution to boiling on high heat, then put the slices in and cover the pot. After the pressure cooker starts to spray, turn to medium heat, turn off the heat after 2 minutes, open the lid after the pressure drops, and cool naturally to room temperature); 4) Inactivate endogenous peroxidase: rinse with PBS buffer 3 times, 1 minute each time, remove the buffer on the slices; immerse the slices completely in 3% hydrogen peroxide solution, and incubate at room temperature for 10 minutes; 5) Block: rinse with PBS buffer 3 times, 3 minutes each time, remove the buffer on the slices; circle the tissue area to be tested on the slide with an immunohistochemical pen, and drop Add PBS blocking solution; place the slices horizontally in an incubation wet box with water at the bottom, incubate at room temperature for 30 minutes, and start timing from the addition of the blocking solution; 6) Primary antibody incubation: remove the blocking solution, add anti-CD63 rabbit monoclonal antibody diluted 1:25 with antibody diluent-PBS working solution on the tissue slices, place horizontally in an incubation wet box, and incubate at room temperature for 60 minutes; remove the antibody working solution, quickly rinse once with PBS buffer, and soak and wash three times with PBS buffer, each time for 3 minutes; during the soaking and washing period, it is necessary to repeatedly pull up and down several times; 7) Secondary antibody incubation: add ready-to-use secondary antibody working solution (Dako REAL EnVision Detection System, Peroxidase / DAB, Rabbit / Mouse, HRP; purchased from Dako, item number K5007) and then placed horizontally in an incubation wet box and incubated at room temperature for 25 minutes; remove the secondary antibody working solution on the slice, quickly rinse once with PBS buffer, and soak and wash three times with PBS buffer, each time for 3 minutes; during the soaking and washing period, it is necessary to repeatedly pull up and down several times; 8) Color development: add color development solution to the slice, closely observe the color change under a microscope, and after obtaining the appropriate staining intensity, immerse the slice in a large amount of distilled water to stop the color development. After the color development is stopped, wash the slice in running water for 10 minutes; 9) Re-staining: Immerse the slightly drained tissue slices in Mayer's hematoxylin for 1 minute, then wash with running water for 3 minutes; 10) Re-blueing: Immerse the slightly drained slices in a saturated aqueous solution of lithium carbonate for 3 seconds, and wash with running water for 3 minutes; 11) Dehydration: Soak the washed slices in anhydrous ethanol once, lift them up and down several times during the soaking period, and take them out after 10 seconds; place them in a constant temperature blast drying oven at high temperature (54-58℃) to completely dry; 12) Sealing: Add an appropriate amount of neutral gum to the center of the slice, and cover it with a cover glass. The amount of glue added should be appropriate. After sealing the cover glass, the tissue should be completely covered, and no glue should overflow; 13) Finally, scan the slices. .
[0103] Immunohistochemical staining results are divided into: positive (brown staining in specific tissues and cells) and negative (no brown staining in specific tissues and cells). Positive expression requires brown staining in specific antigen sites of tissues and cells and low background color in antigen-free sites (cells and tissues that theoretically should not be stained), that is, no nonspecific staining. For example, in the positive sample, CD63 protein is highly expressed in the cytoplasm and cell membrane of human melanoma cells, and the corresponding sites should be brown, and the rest of the sites should not be stained brown ( Figure 4 ); In human colon tissue samples, CD63 protein is highly expressed in the cytoplasm and cell membrane of monocytes and macrophages, showing brown positive staining, while colon epithelial cells and other cells are negative and have no brown staining ( Figure 5 ). The cell nucleus is counterstained with hematoxylin and appears blue, which can show the background outline of cells with specific immunostaining and is used to determine the subcellular localization of the target protein CD63.
[0104] In this embodiment, all 7 positive samples were positively stained, and 6 of the 6 negative samples were negative, with a sensitivity of 13 / 13=100%. The specific positive control samples were: 1 / 1 human lung, 1 / 1 human lung cancer, 1 / 1 human colon, 2 / 2 human colon cancer, 1 / 1 human tonsil, 1 / 1 human malignant melanoma scattered lymphocytes were positively stained, with a sensitivity of 7 / 7=100%; negative samples: 1 / 1 human esophagus, 1 / 1 human esophageal cancer, 1 / 1 human placenta, 1 / 1 human liver, 1 / 1 human liver cancer, 1 / 1 human breast cancer were positive only for macrophages and monocytes, and the rest of the cells were negative, which was consistent with the theoretical positioning and was recorded as negative, with a specificity of 6 / 6=100%. Some positive results are shown in Figure 4-5 ,in Figure 4 shows the results of immunohistochemical staining of human malignant melanoma, Figure 5 The results of immunohistochemical staining of human colon are shown, and some negative results are shown in Figure 6 , which shows the immunohistochemical staining results of human breast cancer. The results show that the anti-human CD63 rabbit monoclonal antibody prepared by the present invention has accurate staining positioning, clear staining without non-specific staining, and a clean background.
[0105] Combined with the results of immunoblotting, it is proved that the anti-human CD63 rabbit monoclonal antibody prepared by the present invention can specifically recognize the human CD63 protein expressed in cells and tissues, has no nonspecific binding and staining during immunoassay, can effectively avoid false positive results, and meet the requirements of high accuracy and high precision detection of pathological samples.
[0106] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A rabbit monoclonal antibody against human lysosomal associated membrane protein 3, characterized in that: It comprises a light chain variable region and a heavy chain variable region, wherein the amino acid sequences of the complementary determining regions CDR1, CDR2 and CDR3 on the light chain variable region are shown as SEQ ID NO.5, SEQ ID NO.6 and SEQ ID NO.7, respectively, and the amino acid sequences of the complementary determining regions CDR1, CDR2 and CDR3 on the heavy chain variable region are shown as SEQ ID NO.8, SEQ ID NO.9 and SEQ ID NO.10, respectively.
2. The rabbit monoclonal antibody against human lysosomal associated membrane protein 3 according to claim 1, characterized in that: The amino acid sequence of the light chain variable region is shown in SEQ ID NO.3, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.
4.
3. The rabbit monoclonal antibody against human lysosomal associated membrane protein 3 according to claim 2, characterized in that: The amino acid sequence of the light chain of the rabbit monoclonal antibody is shown in SEQ ID NO.1, and the amino acid sequence of the heavy chain is shown in SEQ ID NO.
2.
4. The rabbit monoclonal antibody against human lysosomal associated membrane protein 3 according to claim 1, characterized in that: The rabbit monoclonal antibody is a full-length antibody or an antibody fragment with immunological activity; the antibody fragment is selected from at least one of a Fab fragment, a F(ab)2 fragment, a Fv fragment, a (Fv)2 fragment, a scFv fragment and a sc(Fv)2 fragment.
5. An antibody conjugate, characterized in that: The method comprises the rabbit monoclonal antibody against human lysosomal associated membrane protein 3 according to any one of claims 1 to 4, and a detection label connected to the rabbit monoclonal antibody.
6. The antibody conjugate according to claim 5, characterized in that The detection label is selected from one or more of biotin, fluorescein, chemiluminescent group, chemical fluorescent group, fluorescent protein, horseradish peroxidase, acid phosphatase, colloidal gold, colored magnetic beads, magnetic microspheres, latex particles, radioactive nuclides and detection antibodies.
7. A nucleic acid molecule, a recombinant vector or a host cell comprising the nucleic acid molecule, characterized in that: The nucleic acid molecule encodes the rabbit monoclonal antibody against human lysosomal-associated membrane protein 3 as described in any one of claims 1 to 4.
8. Use of the anti-human lysosomal associated membrane protein 3 rabbit monoclonal antibody according to any one of claims 1 to 4, or the antibody conjugate according to any one of claims 5 to 6 in the preparation of a human lysosomal associated membrane protein 3 immunoassay kit.
9. A human lysosomal associated membrane protein 3 immunoassay kit, characterized in that: The kit comprises the rabbit monoclonal antibody against human lysosomal associated membrane protein 3 as described in any one of claims 1 to 4, or the antibody conjugate as described in any one of claims 5 to 6.
10. The human lysosomal associated membrane protein 3 immunoassay kit according to claim 9, characterized in that: The kit is an immunoblotting kit or an immunohistochemistry kit.
